PointState Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

PointState Capital’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-155,000	Closed	-$19.9M	–	139
2016 Q1	$19.9M	Buy	+155,000	New	+$18.3M	0.54%	30
2014 Q1	–	Sell	-200,000	Closed	-$13.7M	–	158
2013 Q4	$13.7M	Sell	200,000 -100,000	-33%	-$5.78M	0.17%	85
2013 Q3	$20.7M	Sell	300,000 -30,000	-9%	-$1.48M	0.35%	58
2013 Q2	$14.8M	Buy	+330,000	New	+$11.3M	0.25%	77

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

PointState Capital's ICPT Position: Q2 2016 in Review

PointState Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2016, closing a stake of 155,000 shares — an estimated $19.9M sold.

PointState Capital first reported a position in ICPT in Q2 2013 and held it in 4 quarters. The position peaked at $20.7M in Q3 2013. 167 funds tracked by Wall St. Rank hold ICPT as of Q2 2016.

PointState Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
PointState Capital sold 155,000 Intercept Pharmaceuticals, Inc. shares in Q2 2016, an estimated $19.9M.
PointState Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 4 quarters.
PointState Capital's Intercept Pharmaceuticals, Inc. position peaked at $20.7M in Q3 2013.
167 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2016.

Based on PointState Capital's 13F filing for Q2 2016, filed 15 Aug 2016.